Literature DB >> 27836797

FISH Panel for Leukemic CTCL.

Jason Weed1, Juliet Gibson1, Julia Lewis1, Kacie Carlson1, Francine Foss1, Jaehyuk Choi2, Peining Li3, Michael Girardi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27836797      PMCID： PMC5419071          DOI： 10.1016/j.jid.2016.10.037

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  12 in total

Review 1.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

2.  Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.

Authors:  S Nakahata; S Yamazaki; H Nakauchi; K Morishita
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

3.  The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells.

Authors:  Jun Wang; Seungsoo Lee; Charis En-Yi Teh; Karen Bunting; Lina Ma; M Frances Shannon
Journal:  Int Immunol       Date:  2009-01-30       Impact factor: 4.823

4.  Novel and highly recurrent chromosomal alterations in Sézary syndrome.

Authors:  Maarten H Vermeer; Remco van Doorn; Remco Dijkman; Xin Mao; Sean Whittaker; Pieter C van Voorst Vader; Marie-Jeanne P Gerritsen; Marie-Louise Geerts; Sylke Gellrich; Ola Söderberg; Karl-Johan Leuchowius; Ulf Landegren; Jacoba J Out-Luiting; Jeroen Knijnenburg; Marije Ijszenga; Karoly Szuhai; Rein Willemze; Cornelis P Tensen
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

5.  Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma.

Authors:  Tomonori Hidaka; Shingo Nakahata; Kinta Hatakeyama; Makoto Hamasaki; Kiyoshi Yamashita; Takashi Kohno; Yasuhito Arai; Tomohiko Taki; Kazuhiro Nishida; Akihiko Okayama; Yujiro Asada; Ryoji Yamaguchi; Hirohito Tsubouchi; Jun Yokota; Masafumi Taniwaki; Yujiro Higashi; Kazuhiro Morishita
Journal:  Blood       Date:  2008-05-08       Impact factor: 22.113

6.  Preclinical validation of fluorescence in situ hybridization assays for clinical practice.

Authors:  Anne E Wiktor; Daniel L Van Dyke; Peggy J Stupca; Rhett P Ketterling; Erik C Thorland; Brandon M Shearer; Stephanie R Fink; Kimberly J Stockero; Jason R Majorowicz; Gordon W Dewald
Journal:  Genet Med       Date:  2006-01       Impact factor: 8.822

7.  Genomic landscape of cutaneous T cell lymphoma.

Authors:  Jaehyuk Choi; Gerald Goh; Trent Walradt; Bok S Hong; Christopher G Bunick; Kan Chen; Robert D Bjornson; Yaakov Maman; Tiffany Wang; Jesse Tordoff; Kacie Carlson; John D Overton; Kristina J Liu; Julia M Lewis; Lesley Devine; Lisa Barbarotta; Francine M Foss; Antonio Subtil; Eric C Vonderheid; Richard L Edelson; David G Schatz; Titus J Boggon; Michael Girardi; Richard P Lifton
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 38.330

8.  High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Authors:  Paolo Nuciforo; Sheeno Thyparambil; Claudia Aura; Ana Garrido-Castro; Marta Vilaro; Vicente Peg; José Jimenez; Rocio Vicario; Fabiola Cecchi; William Hoos; Jon Burrows; Todd Hembrough; Juan Carles Ferreres; José Perez-Garcia; Joaquin Arribas; Javier Cortes; Maurizio Scaltriti
Journal:  Mol Oncol       Date:  2015-09-15       Impact factor: 6.603

9.  Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.

Authors:  Mark J Kiel; Anagh A Sahasrabuddhe; Delphine C M Rolland; Thirunavukkarasu Velusamy; Fuzon Chung; Matthew Schaller; Nathanael G Bailey; Bryan L Betz; Roberto N Miranda; Pierluigi Porcu; John C Byrd; L Jeffrey Medeiros; Steven L Kunkel; David W Bahler; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Nat Commun       Date:  2015-09-29       Impact factor: 14.919

10.  The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Authors:  Daniel L Van Dyke; Lillian Werner; Laura Z Rassenti; Donna Neuberg; Emanuella Ghia; Nyla A Heerema; Paola Dal Cin; Marie Dell Aquila; Chandrika Sreekantaiah; Andrew W Greaves; Thomas J Kipps; Neil E Kay
Journal:  Br J Haematol       Date:  2016-02-05       Impact factor: 6.998
View more
  8 in total

1.  Single-cell heterogeneity in Sézary syndrome.

Authors:  Terkild Brink Buus; Andreas Willerslev-Olsen; Simon Fredholm; Edda Blümel; Claudia Nastasi; Maria Gluud; Tengpeng Hu; Lise M Lindahl; Lars Iversen; Hanne Fogh; Robert Gniadecki; Ivan V Litvinov; Jenny L Persson; Charlotte Menné Bonefeld; Carsten Geisler; Jan Pravsgaard Christensen; Thorbjørn Krejsgaard; Thomas Litman; Anders Woetmann; Niels Ødum
Journal:  Blood Adv       Date:  2018-08-28

2.  JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Amber Loren O King; Sa Rang Kim; Kacie R Carlson; Sheila R Umlauf; Yulia V Surovtseva; Francine M Foss; Michael Girardi
Journal:  Blood Adv       Date:  2020-05-26

Review 3.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

4.  Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

Authors:  Benoit M Cyrenne; Julia M Lewis; Jason G Weed; Kacie R Carlson; Fatima N Mirza; Francine M Foss; Michael Girardi
Journal:  Blood       Date:  2017-10-02       Impact factor: 22.113

5.  TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.

Authors:  Audrey Gros; Elodie Laharanne; Marie Vergier; Martina Prochazkova-Carlotti; Anne Pham-Ledard; Thomas Bandres; Sandrine Poglio; Sabine Berhouet; Béatrice Vergier; Jean-Philippe Vial; Edith Chevret; Marie Beylot-Barry; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

6.  CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Kacie R Carlson; Brett King; Shawn Cowper; Christopher G Bunick; Jennifer McNiff; Michael Girardi
Journal:  JAAD Case Rep       Date:  2020-04-30

7.  BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.

Authors:  Sa Rang Kim; Julia M Lewis; Benoit M Cyrenne; Patrick F Monico; Fatima N Mirza; Kacie R Carlson; Francine M Foss; Michael Girardi
Journal:  Oncotarget       Date:  2018-06-26

Review 8.  Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.

Authors:  Sara Yumeen; Michael Girardi
Journal:  Yale J Biol Med       Date:  2020-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.